Trial Profile

A comparison study of orviglance versus the gadolinium contrast agent for detection of liver disorder

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CMC 001 (Primary) ; Gadobenic acid
Indications Liver disorders
Focus Diagnostic use

Most Recent Events

08 Apr 2025 According to an Ascelia Pharma Media Release, the publication in the Investigative Radiology is co-authored by Torkel Brismar, MD, PhD and Nikolaos Kartalis MD, PhD from the Department of Radiology, Karolinska University Hospital, Stockholm.
08 Apr 2025 According to an Ascelia Pharma Media Release, data from this study were published in the journal Investigative Radiology.
08 Apr 2025 Results published in an Ascelia Pharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com